肺癌：热休克蛋白70与瓣内切核酸酶1蛋白的相关性进展
Lung cancer: progression of heat shock protein 70 in association with flap endonuclease 1 protein.
作者信息
Kathera Chandra Sekhar, Longwei Jiang, Janardhan Avilala, Qin Lihong, Zhang Qi, Lan Wu, Shaochang Jia, Guo Zhigang
机构信息
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing, 210023 Jiangsu China.
Obstetrics and Gynaecology Hospital, Affiliated to Nanjing Medical University, Nanjing, 210023 China.
出版信息
3 Biotech. 2021 Mar;11(3):141. doi: 10.1007/s13205-020-02598-3. Epub 2021 Feb 25.
UNLABELLED
Lung cancer is one of the leading causes of cancer deaths worldwide and existing approaches are not enough to manage, and hence, it is important to concentrate on new drug strategies. This study was aimed to identify the interacting partner of Flap endonuclease 1 (FEN1) and its role in cancer treatment. We identified a new FEN1 interacting partner confirmed it as Heat Shock Protein 70 (HSP 70), and its effect on FEN1 expression, in vitro. Additionally, we found that the 5-Fluorouracil's (5-FU) function was significantly improved when used in combination with HSP 70 inhibitor (KNK 437). The findings are interesting, elucidating the synergistic mechanism between two compounds which helps to develop a novel management strategy for over-expressed FEN1 in the lung.
SUPPLEMENTARY INFORMATION
The online version contains supplementary material available at 10.1007/s13205-020-02598-3.
未标注
肺癌是全球癌症死亡的主要原因之一，现有治疗方法不足以应对，因此，专注于新的药物策略很重要。本研究旨在确定翼状内切酶1（FEN1）的相互作用伙伴及其在癌症治疗中的作用。我们鉴定出一种新的FEN1相互作用伙伴，证实其为热休克蛋白70（HSP 70），并在体外研究了其对FEN1表达的影响。此外，我们发现5-氟尿嘧啶（5-FU）与HSP 70抑制剂（KNK 437）联合使用时，其功能显著改善。这些发现很有趣，阐明了两种化合物之间的协同机制，有助于为肺中FEN1过表达开发新的治疗策略。
补充信息
在线版本包含可在10.1007/s13205-020-02598-3获取的补充材料。
Zotero 插件